|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
4
|
Morphine
|
Cataract
|
1110410
|
375545
|
Morphine & Cataract
|
## Chronograph ##

## Basic demographic table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
327
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
185
|
57
|
Sex
|
gender = FEMALE
|
613
|
61
|
Sex
|
gender = FEMALE
|
560
|
56
|
Sex
|
gender = FEMALE
|
546
|
55
|
|
|
gender = MALE
|
142
|
43
|
|
gender = MALE
|
387
|
39
|
|
gender = MALE
|
440
|
44
|
|
gender = MALE
|
454
|
45
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
3
|
1
|
|
(20,30]
|
5
|
0
|
|
(20,30]
|
6
|
1
|
|
(20,30]
|
9
|
1
|
|
|
(30,40]
|
9
|
3
|
|
(30,40]
|
28
|
3
|
|
(30,40]
|
18
|
2
|
|
(30,40]
|
11
|
1
|
|
|
(40,50]
|
7
|
2
|
|
(40,50]
|
54
|
5
|
|
(40,50]
|
34
|
3
|
|
(40,50]
|
42
|
4
|
|
|
(50,60]
|
19
|
6
|
|
(50,60]
|
64
|
6
|
|
(50,60]
|
57
|
6
|
|
(50,60]
|
57
|
6
|
|
|
(60,70]
|
88
|
27
|
|
(60,70]
|
204
|
20
|
|
(60,70]
|
223
|
22
|
|
(60,70]
|
230
|
23
|
|
|
(70,80]
|
109
|
33
|
|
(70,80]
|
369
|
37
|
|
(70,80]
|
361
|
36
|
|
(70,80]
|
386
|
39
|
|
|
(80,90]
|
73
|
22
|
|
(80,90]
|
228
|
23
|
|
(80,90]
|
228
|
23
|
|
(80,90]
|
222
|
22
|
|
|
(90,110]
|
19
|
6
|
|
(90,110]
|
48
|
5
|
|
(90,110]
|
73
|
7
|
|
(90,110]
|
43
|
4
|
|
|
Median
|
74
|
IQR=(68, 81)
|
|
Median
|
74
|
IQR=(68, 82)
|
|
Median
|
75
|
IQR=(68, 82)
|
|
Median
|
74
|
IQR=(68, 81)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 327)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 327)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
0.6
|
2.2
|
0.14
|
|
25 - 29
|
0.9
|
0.4
|
-0.06
|
Visual system disorder
|
50.8
|
31.7
|
-0.39
|
|
30 - 34
|
0.3
|
1.0
|
0.09
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.8
|
1.3
|
-0.04
|
Atrial fibrillation
|
45.0
|
29.9
|
-0.31
|
|
40 - 44
|
0.9
|
2.3
|
0.11
|
Cerebrovascular disease
|
14.1
|
10.9
|
-0.10
|
|
45 - 49
|
1.2
|
2.9
|
0.12
|
Coronary arteriosclerosis
|
46.5
|
34.6
|
-0.24
|
|
50 - 54
|
1.5
|
3.2
|
0.11
|
Heart disease
|
80.4
|
63.6
|
-0.38
|
|
55 - 59
|
3.4
|
3.3
|
0.00
|
Heart failure
|
37.3
|
28.3
|
-0.19
|
|
60 - 64
|
5.5
|
3.4
|
-0.10
|
Ischemic heart disease
|
21.1
|
16.8
|
-0.11
|
|
65 - 69
|
15.9
|
14.3
|
-0.04
|
Peripheral vascular disease
|
42.8
|
32.2
|
-0.22
|
|
70 - 74
|
20.5
|
20.2
|
-0.01
|
Pulmonary embolism
|
6.1
|
3.1
|
-0.14
|
|
75 - 79
|
17.1
|
17.5
|
0.01
|
Venous thrombosis
|
9.8
|
8.2
|
-0.06
|
|
80 - 84
|
14.4
|
13.4
|
-0.03
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
9.2
|
10.4
|
0.04
|
Hematologic neoplasm
|
14.1
|
10.5
|
-0.11
|
|
90 - 94
|
4.6
|
3.9
|
-0.03
|
Malignant lymphoma
|
8.9
|
4.4
|
-0.18
|
|
95 - 99
|
2.1
|
2.0
|
-0.01
|
Malignant neoplasm of anorectum
|
1.2
|
0.8
|
-0.04
|
|
100 - 104
|
0.6
|
0.5
|
-0.02
|
Malignant neoplastic disease
|
42.5
|
31.3
|
-0.23
|
|
Gender: female
|
56.6
|
61.3
|
0.10
|
Malignant tumor of breast
|
6.7
|
5.4
|
-0.06
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
7.6
|
3.4
|
-0.19
|
|
Acute respiratory disease
|
33.0
|
25.0
|
-0.18
|
Malignant tumor of lung
|
4.9
|
3.9
|
-0.05
|
|
Attention deficit hyperactivity disorder
|
0.9
|
0.5
|
-0.05
|
Malignant tumor of urinary bladder
|
6.4
|
3.6
|
-0.13
|
|
Chronic liver disease
|
3.4
|
3.6
|
0.01
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
17.1
|
11.4
|
-0.16
|
Agents acting on the renin-angiotensin system
|
59.0
|
64.7
|
0.12
|
|
Crohn’s disease
|
0.9
|
1.0
|
0.01
|
Antibacterials for systemic use
|
51.7
|
47.5
|
-0.08
|
|
Dementia
|
16.8
|
15.7
|
-0.03
|
Antidepressants
|
51.4
|
54.3
|
0.06
|
|
Depressive disorder
|
14.1
|
13.2
|
-0.03
|
Antiepileptics
|
30.6
|
33.6
|
0.06
|
|
Diabetes mellitus
|
71.9
|
57.9
|
-0.30
|
Antiinflammatory and antirheumatic products
|
36.4
|
37.0
|
0.01
|
|
Gastroesophageal reflux disease
|
20.5
|
18.1
|
-0.06
|
Antineoplastic agents
|
16.5
|
12.9
|
-0.10
|
|
Gastrointestinal hemorrhage
|
12.8
|
7.3
|
-0.18
|
Antipsoriatics
|
0
|
0.6
|
0.11
|
|
Human immunodeficiency virus infection
|
0.9
|
1.4
|
0.05
|
Antithrombotic agents
|
47.7
|
46.5
|
-0.02
|
|
Hyperlipidemia
|
38.2
|
28.9
|
-0.20
|
Beta blocking agents
|
54.1
|
56.4
|
0.05
|
|
Hypertensive disorder
|
7.0
|
4.6
|
-0.10
|
Calcium channel blockers
|
42.8
|
47.4
|
0.09
|
|
Lesion of liver
|
4.0
|
4.3
|
0.02
|
Diuretics
|
58.1
|
62.7
|
0.09
|
|
Obesity
|
9.5
|
6.7
|
-0.10
|
Drugs for acid related disorders
|
37.0
|
45.4
|
0.17
|
|
Osteoarthritis
|
55.0
|
46.2
|
-0.18
|
Drugs for obstructive airway diseases
|
33.9
|
34.5
|
0.01
|
|
Pneumonia
|
9.5
|
6.5
|
-0.11
|
Drugs used in diabetes
|
47.1
|
51.2
|
0.08
|
|
Psoriasis
|
1.8
|
2.2
|
0.03
|
Immunosuppressants
|
6.1
|
6.0
|
0.00
|
|
Renal impairment
|
35.8
|
28.9
|
-0.15
|
Lipid modifying agents
|
60.9
|
65.1
|
0.09
|
|
Rheumatoid arthritis
|
8.0
|
7.2
|
-0.03
|
Opioids
|
31.2
|
35.1
|
0.08
|
|
Schizophrenia
|
8.3
|
7.0
|
-0.05
|
Psycholeptics
|
52.6
|
54.1
|
0.03
|
|
Ulcerative colitis
|
0.6
|
0.7
|
0.01
|
Psychostimulants, agents used for adhd and nootropics
|
10.7
|
15.3
|
0.14
|
|
Urinary tract infectious disease
|
30.9
|
23.0
|
-0.18
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
1.3
|
1.6
|
0.03
|
|
25 - 29
|
0.4
|
0.6
|
0.03
|
Visual system disorder
|
45.9
|
32.3
|
-0.28
|
|
30 - 34
|
0.5
|
0.8
|
0.04
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.3
|
0.4
|
-0.10
|
Atrial fibrillation
|
36.8
|
28.2
|
-0.18
|
|
40 - 44
|
1.2
|
0.9
|
-0.03
|
Cerebrovascular disease
|
14.2
|
9.2
|
-0.16
|
|
45 - 49
|
2.1
|
3.0
|
0.06
|
Coronary arteriosclerosis
|
40.3
|
29.6
|
-0.23
|
|
50 - 54
|
2.0
|
2.7
|
0.05
|
Heart disease
|
73.9
|
57.7
|
-0.35
|
|
55 - 59
|
3.9
|
2.8
|
-0.06
|
Heart failure
|
33.4
|
23.9
|
-0.21
|
|
60 - 64
|
2.6
|
3.1
|
0.03
|
Ischemic heart disease
|
20.0
|
13.4
|
-0.18
|
|
65 - 69
|
16.3
|
15.6
|
-0.02
|
Peripheral vascular disease
|
38.5
|
27.9
|
-0.23
|
|
70 - 74
|
18.3
|
22.5
|
0.10
|
Pulmonary embolism
|
3.6
|
2.4
|
-0.07
|
|
75 - 79
|
18.9
|
18.1
|
-0.02
|
Venous thrombosis
|
10.4
|
8.8
|
-0.05
|
|
80 - 84
|
12.8
|
13.9
|
0.03
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.0
|
9.4
|
-0.05
|
Hematologic neoplasm
|
12.4
|
8.6
|
-0.12
|
|
90 - 94
|
4.9
|
3.9
|
-0.05
|
Malignant lymphoma
|
4.9
|
3.8
|
-0.05
|
|
95 - 99
|
3.1
|
2.0
|
-0.07
|
Malignant neoplasm of anorectum
|
2.5
|
2.1
|
-0.03
|
|
100 - 104
|
0.7
|
0.3
|
-0.06
|
Malignant neoplastic disease
|
36.1
|
28.5
|
-0.16
|
|
Gender: female
|
56.0
|
54.6
|
-0.03
|
Malignant tumor of breast
|
4.7
|
3.8
|
-0.04
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.3
|
3.3
|
-0.10
|
|
Acute respiratory disease
|
26.2
|
20.4
|
-0.14
|
Malignant tumor of lung
|
4.0
|
4.6
|
0.03
|
|
Attention deficit hyperactivity disorder
|
0.5
|
0.1
|
-0.07
|
Malignant tumor of urinary bladder
|
4.3
|
3.0
|
-0.07
|
|
Chronic liver disease
|
3.2
|
3.6
|
0.02
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
11.1
|
8.4
|
-0.09
|
Agents acting on the renin-angiotensin system
|
41.1
|
0
|
-1.18
|
|
Crohn’s disease
|
0.8
|
0.7
|
-0.01
|
Antibacterials for systemic use
|
34.4
|
0
|
-1.02
|
|
Dementia
|
13.9
|
11.5
|
-0.07
|
Antidepressants
|
34.0
|
0
|
-1.02
|
|
Depressive disorder
|
9.8
|
7.1
|
-0.10
|
Antiepileptics
|
18.1
|
0
|
-0.66
|
|
Diabetes mellitus
|
64.2
|
48.8
|
-0.31
|
Antiinflammatory and antirheumatic products
|
20.3
|
0
|
-0.71
|
|
Gastroesophageal reflux disease
|
18.1
|
13.9
|
-0.11
|
Antineoplastic agents
|
12.0
|
0
|
-0.52
|
|
Gastrointestinal hemorrhage
|
8.5
|
5.8
|
-0.10
|
Antipsoriatics
|
0.5
|
0
|
-0.10
|
|
Human immunodeficiency virus infection
|
0.4
|
0.4
|
0.00
|
Antithrombotic agents
|
32.1
|
0
|
-0.97
|
|
Hyperlipidemia
|
34.4
|
24.0
|
-0.23
|
Beta blocking agents
|
36.3
|
0
|
-1.07
|
|
Hypertensive disorder
|
5.4
|
4.9
|
-0.02
|
Calcium channel blockers
|
29.7
|
0
|
-0.92
|
|
Lesion of liver
|
4.2
|
4.1
|
-0.01
|
Diuretics
|
43.5
|
0
|
-1.24
|
|
Obesity
|
8.0
|
5.6
|
-0.10
|
Drugs for acid related disorders
|
26.0
|
0
|
-0.84
|
|
Osteoarthritis
|
53.8
|
40.7
|
-0.26
|
Drugs for obstructive airway diseases
|
22.0
|
0
|
-0.75
|
|
Pneumonia
|
4.6
|
5.4
|
0.04
|
Drugs used in diabetes
|
29.4
|
0
|
-0.91
|
|
Psoriasis
|
2.3
|
1.7
|
-0.04
|
Immunosuppressants
|
4.5
|
0
|
-0.31
|
|
Renal impairment
|
27.6
|
22.1
|
-0.13
|
Lipid modifying agents
|
42.5
|
0
|
-1.22
|
|
Rheumatoid arthritis
|
7.5
|
7.0
|
-0.02
|
Opioids
|
20.3
|
0
|
-0.71
|
|
Schizophrenia
|
4.4
|
4.3
|
0.00
|
Psycholeptics
|
33.3
|
0
|
-1.00
|
|
Ulcerative colitis
|
0.3
|
0.2
|
-0.02
|
Psychostimulants, agents used for adhd and nootropics
|
8.6
|
0
|
-0.43
|
|
Urinary tract infectious disease
|
25.9
|
18.6
|
-0.18
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 1,000)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
1.3
|
1.6
|
0.03
|
|
25 - 29
|
0.4
|
0.6
|
0.03
|
Visual system disorder
|
45.9
|
32.3
|
-0.28
|
|
30 - 34
|
0.5
|
0.8
|
0.04
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.3
|
0.4
|
-0.10
|
Atrial fibrillation
|
36.8
|
28.2
|
-0.18
|
|
40 - 44
|
1.2
|
0.9
|
-0.03
|
Cerebrovascular disease
|
14.2
|
9.2
|
-0.16
|
|
45 - 49
|
2.1
|
3.0
|
0.06
|
Coronary arteriosclerosis
|
40.3
|
29.6
|
-0.23
|
|
50 - 54
|
2.0
|
2.7
|
0.05
|
Heart disease
|
73.9
|
57.7
|
-0.35
|
|
55 - 59
|
3.9
|
2.8
|
-0.06
|
Heart failure
|
33.4
|
23.9
|
-0.21
|
|
60 - 64
|
2.6
|
3.1
|
0.03
|
Ischemic heart disease
|
20.0
|
13.4
|
-0.18
|
|
65 - 69
|
16.3
|
15.6
|
-0.02
|
Peripheral vascular disease
|
38.5
|
27.9
|
-0.23
|
|
70 - 74
|
18.3
|
22.5
|
0.10
|
Pulmonary embolism
|
3.6
|
2.4
|
-0.07
|
|
75 - 79
|
18.9
|
18.1
|
-0.02
|
Venous thrombosis
|
10.4
|
8.8
|
-0.05
|
|
80 - 84
|
12.8
|
13.9
|
0.03
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.0
|
9.4
|
-0.05
|
Hematologic neoplasm
|
12.4
|
8.6
|
-0.12
|
|
90 - 94
|
4.9
|
3.9
|
-0.05
|
Malignant lymphoma
|
4.9
|
3.8
|
-0.05
|
|
95 - 99
|
3.1
|
2.0
|
-0.07
|
Malignant neoplasm of anorectum
|
2.5
|
2.1
|
-0.03
|
|
100 - 104
|
0.7
|
0.3
|
-0.06
|
Malignant neoplastic disease
|
36.1
|
28.5
|
-0.16
|
|
Gender: female
|
56.0
|
54.6
|
-0.03
|
Malignant tumor of breast
|
4.7
|
3.8
|
-0.04
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.3
|
3.3
|
-0.10
|
|
Acute respiratory disease
|
26.2
|
20.4
|
-0.14
|
Malignant tumor of lung
|
4.0
|
4.6
|
0.03
|
|
Attention deficit hyperactivity disorder
|
0.5
|
0.1
|
-0.07
|
Malignant tumor of urinary bladder
|
4.3
|
3.0
|
-0.07
|
|
Chronic liver disease
|
3.2
|
3.6
|
0.02
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
11.1
|
8.4
|
-0.09
|
Agents acting on the renin-angiotensin system
|
41.1
|
0
|
-1.18
|
|
Crohn’s disease
|
0.8
|
0.7
|
-0.01
|
Antibacterials for systemic use
|
34.4
|
0
|
-1.02
|
|
Dementia
|
13.9
|
11.5
|
-0.07
|
Antidepressants
|
34.0
|
0
|
-1.02
|
|
Depressive disorder
|
9.8
|
7.1
|
-0.10
|
Antiepileptics
|
18.1
|
0
|
-0.66
|
|
Diabetes mellitus
|
64.2
|
48.8
|
-0.31
|
Antiinflammatory and antirheumatic products
|
20.3
|
0
|
-0.71
|
|
Gastroesophageal reflux disease
|
18.1
|
13.9
|
-0.11
|
Antineoplastic agents
|
12.0
|
0
|
-0.52
|
|
Gastrointestinal hemorrhage
|
8.5
|
5.8
|
-0.10
|
Antipsoriatics
|
0.5
|
0
|
-0.10
|
|
Human immunodeficiency virus infection
|
0.4
|
0.4
|
0.00
|
Antithrombotic agents
|
32.1
|
0
|
-0.97
|
|
Hyperlipidemia
|
34.4
|
24.0
|
-0.23
|
Beta blocking agents
|
36.3
|
0
|
-1.07
|
|
Hypertensive disorder
|
5.4
|
4.9
|
-0.02
|
Calcium channel blockers
|
29.7
|
0
|
-0.92
|
|
Lesion of liver
|
4.2
|
4.1
|
-0.01
|
Diuretics
|
43.5
|
0
|
-1.24
|
|
Obesity
|
8.0
|
5.6
|
-0.10
|
Drugs for acid related disorders
|
26.0
|
0
|
-0.84
|
|
Osteoarthritis
|
53.8
|
40.7
|
-0.26
|
Drugs for obstructive airway diseases
|
22.0
|
0
|
-0.75
|
|
Pneumonia
|
4.6
|
5.4
|
0.04
|
Drugs used in diabetes
|
29.4
|
0
|
-0.91
|
|
Psoriasis
|
2.3
|
1.7
|
-0.04
|
Immunosuppressants
|
4.5
|
0
|
-0.31
|
|
Renal impairment
|
27.6
|
22.1
|
-0.13
|
Lipid modifying agents
|
42.5
|
0
|
-1.22
|
|
Rheumatoid arthritis
|
7.5
|
7.0
|
-0.02
|
Opioids
|
20.3
|
0
|
-0.71
|
|
Schizophrenia
|
4.4
|
4.3
|
0.00
|
Psycholeptics
|
33.3
|
0
|
-1.00
|
|
Ulcerative colitis
|
0.3
|
0.2
|
-0.02
|
Psychostimulants, agents used for adhd and nootropics
|
8.6
|
0
|
-0.43
|
|
Urinary tract infectious disease
|
25.9
|
18.6
|
-0.18
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
beta blocking agents
|
354
|
|
antithrombotic agents
|
312
|
|
nervous system
|
277
|
|
cardiovascular system
|
266
|
|
alimentary tract and metabolism
|
263
|
|
respiratory system
|
226
|
|
blood and blood forming organs
|
211
|
|
antiepileptics
|
200
|
|
lipid modifying agents
|
199
|
|
lipid modifying agents, plain
|
199
|
|
sensory organs
|
199
|
|
all other therapeutic products
|
198
|
|
ophthalmologicals
|
198
|
|
analgesics
|
197
|
|
agents acting on the renin-angiotensin system
|
193
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
193
|
|
stomatological preparations
|
192
|
|
diuretics
|
190
|
|
antiinfectives for systemic use
|
184
|
|
psychoanaleptics
|
182
|
|
musculo-skeletal system
|
173
|
|
antihistamines for systemic use
|
172
|
|
psycholeptics
|
172
|
|
hmg coa reductase inhibitors
|
171
|
|
antibacterials for systemic use
|
169
|
|
cond_180_days
|
n_180_days
|
|
inflammation of specific body systems
|
282
|
|
inflammation of specific body organs
|
275
|
|
pain
|
273
|
|
pain finding at anatomical site
|
273
|
|
arthropathy
|
263
|
|
heart disease
|
263
|
|
vascular disorder
|
239
|
|
diabetes mellitus
|
235
|
|
measurement finding outside reference range
|
235
|
|
soft tissue lesion
|
227
|
|
type 2 diabetes mellitus
|
225
|
|
pain of truncal structure
|
221
|
|
neoplastic disease
|
208
|
|
structural disorder of heart
|
192
|
|
cardiac arrhythmia
|
188
|
|
degenerative disorder of musculoskeletal system
|
181
|
|
abnormal blood cell count
|
180
|
|
osteoarthritis
|
180
|
|
measurement finding below reference range
|
174
|
|
arteriosclerotic vascular disease
|
172
|
|
anemia
|
170
|
|
cytopenia
|
170
|
|
erythropenia
|
170
|
|
hemoglobin level outside reference range
|
170
|
|
hemoglobin low
|
170
|